Literature DB >> 20195405

Clinical characteristics of pulmonary embolism with underlying malignancy.

Ji Eun Lee1, Hye-Ryoun Kim, Sang-Min Lee, Jae-Joon Yim, Chul-Gyu Yoo, Young Whan Kim, Sung Koo Han, Young-Soo Shim, Seok-Chul Yang.   

Abstract

BACKGROUND/AIMS: The risk of venous thromboembolism (VTE), which encompasses deep vein thrombosis and pulmonary embolism (PE), increases in patients with cancer. Anticancer treatment is also associated with an increased risk for VTE. We conducted this study to investigate the clinical characteristics of patients with cancer and PE related to anticancer treatment in a tertiary care hospital in Korea.
METHODS: We retrospectively reviewed the clinical data of patients with an underlying malignancy who were diagnosed with PE by chest computed tomography (CT) with or without lower extremity CT angiography between January 2006 and December 2007 at Seoul National University Hospital.
RESULTS: Overall, 95 patients with malignancies among 168 with PE were analyzed. The median age was 64 years. The median time interval from the malignancy diagnosis to the PE diagnosis was 5.5 months. Lung cancer was the most common malignancy (23.0%), followed by pancreatobiliary cancer, stomach cancer, gynecological cancer, breast cancer, and hepatocellular carcinoma. Platinum-containing and pyrimidine analog-containing chemotherapeutic regimens were common.
CONCLUSIONS: PE was diagnosed within 1 year after the cancer diagnosis in almost 70% of patients. Lung cancer was the most common underlying malignancy.

Entities:  

Keywords:  Drug therapy; Neoplasms; Pulmonary embolism; Radiotherapy

Mesh:

Substances:

Year:  2010        PMID: 20195405      PMCID: PMC2829418          DOI: 10.3904/kjim.2010.25.1.66

Source DB:  PubMed          Journal:  Korean J Intern Med        ISSN: 1226-3303            Impact factor:   2.884


  22 in total

1.  Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial.

Authors:  S Schulman; P Lindmarker
Journal:  N Engl J Med       Date:  2000-06-29       Impact factor: 91.245

2.  Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis?

Authors:  D A Sandler; J F Martin
Journal:  J R Soc Med       Date:  1989-04       Impact factor: 5.344

3.  Occult cancer in patients with venous thromboembolism: which patients, which cancers.

Authors:  M Monreal; J Fernandez-Llamazares; J Perandreu; A Urrutia; J C Sahuquillo; E Contel
Journal:  Thromb Haemost       Date:  1997-11       Impact factor: 5.249

4.  Deep-vein thrombosis and the incidence of subsequent symptomatic cancer.

Authors:  P Prandoni; A W Lensing; H R Büller; A Cogo; M H Prins; A M Cattelan; S Cuppini; F Noventa; J W ten Cate
Journal:  N Engl J Med       Date:  1992-10-15       Impact factor: 91.245

5.  Heparin abolishes the chemotherapy-induced increase in plasma fibrinopeptide A levels.

Authors:  R L Edwards; M Klaus; E Matthews; C McCullen; R D Bona; F R Rickles
Journal:  Am J Med       Date:  1990-07       Impact factor: 4.965

6.  The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma.

Authors:  J W Blom; S Osanto; F R Rosendaal
Journal:  J Thromb Haemost       Date:  2004-10       Impact factor: 5.824

7.  Venous thromboembolism: deep vein thrombosis with pulmonary embolism, deep vein thrombosis alone, and pulmonary embolism alone.

Authors:  Masahito Sakuma; Mashio Nakamura; Norikazu Yamada; Satoshi Ota; Kunio Shirato; Takeshi Nakano; Masaaki Ito; Takao Kobayashi
Journal:  Circ J       Date:  2008-12-18       Impact factor: 2.993

8.  Thrombogenicity of intravenous 5-fluorouracil alone or in combination with cisplatin.

Authors:  T Kuzel; B Esparaz; D Green; M Kies
Journal:  Cancer       Date:  1990-02-15       Impact factor: 6.860

9.  Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon.

Authors:  Hans-Martin M B Otten; Joost Mathijssen; Hugo ten Cate; Marcel Soesan; Marijke Inghels; Dick J Richel; Martin H Prins
Journal:  Arch Intern Med       Date:  2004-01-26

10.  Idiopathic deep vein thrombosis in an apparently healthy patient as a premonitory sign of occult cancer.

Authors:  D Aderka; A Brown; A Zelikovski; J Pinkhas
Journal:  Cancer       Date:  1986-05-01       Impact factor: 6.860

View more
  5 in total

1.  Cerebellar abscesses, infective endocarditis and bacteraemia due to a rare pathogen: Streptococcus constellatus.

Authors:  Rafael García Carretero
Journal:  BMJ Case Rep       Date:  2017-09-01

2.  Clinical analysis of tumor and non-tumor patients complicated with pulmonary embolism.

Authors:  Hong Wang; Yuan Huang; Chun-Wei Xu; Li Lin
Journal:  Int J Clin Exp Med       Date:  2015-10-15

Review 3.  The rate and mortality of postoperative venous thromboembolism of moderate risk surgery in Asian patients without thrombo-prophylaxis: systematic review with meta-analysis.

Authors:  Burapa Kanchanabat; Wikoon Stapanavatr; Sumonmal Manusirivithaya; Satid Srimantayamas
Journal:  World J Surg       Date:  2014-01       Impact factor: 3.352

Review 4.  Lung Cancer and Pulmonary Embolism: What Is the Relationship? A Review.

Authors:  Yupeng Li; Yu Shang; Wenwen Wang; Shangwei Ning; Hong Chen
Journal:  J Cancer       Date:  2018-08-06       Impact factor: 4.207

5.  Lung adenocarcinoma and lung squamous cell carcinoma cancer classification, biomarker identification, and gene expression analysis using overlapping feature selection methods.

Authors:  Joe W Chen; Joseph Dhahbi
Journal:  Sci Rep       Date:  2021-06-25       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.